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ABSTRACT 39 
Neuronal ceroid lipofuscinoses (NCL) are a group of incurable lysosomal storage 40 
disorders characterized by neurodegeneration and accumulation of lipopigments 41 
mainly within the neurons. We studied two littermate Chihuahua dogs presenting with 42 
progressive signs of blindness, ataxia, pacing and cognitive impairment from the age 43 
of one year old. Due to worsening of clinical signs, both dogs were euthanized at 44 
around two years of age. Post-mortem examination revealed marked accumulation of 45 
autofluorescent intracellular inclusions within the brain, characteristic of NCL. Whole 46 
genome sequencing was performed on one of the affected dogs. Following sequence 47 
alignment and variant calling against the canine reference genome, variants were 48 
identified in the coding region or splicing regions of four previously known NCL 49 
genes (CLN6, ARSG, CLN2=TPP1 and CLN7=MFSD8). Subsequent segregation 50 
analysis within the family (two affected dogs, both parents and three relatives) 51 
identified MFSD8:p.Phe282Leufs13* as the causal mutation, which had previously 52 
been identified in one Chinese crested dog with no available ancestries. Due to the 53 
similarities of the clinical signs and histopathological changes with the human form of 54 
the disease, we propose that the Chihuahua dog could be a good animal model of 55 
CLN7 disease. 56 
 57 58 
SIGNIFICANCE STATEMENT  59 
NCL are a group of incurable lysosomal storage disorders unified by similar 60 
histopathological changes. Although mutations in 13 genes coding for functionally 61 
distinct proteins have been identified, the pathophysiology of these diseases is still  62 
poorly understood. Naturally occurring large animal models have had an invaluable 63 
contribution to better understand the pathophysiology and therapeutic options of some 64 
forms of NCL. CLN7 is a poorly characterized form, and this could be due to a lack 65 
of animal models that closely reproduce the human phenotype. We identified 66 
Chihuahua dogs with a genetic mutation causing CLN7 disease, which could 67 
represent an excellent animal model. 68 
 69 
INTRODUCTION 70 
Neuronal Ceroid Lipofuscinoses (NCL) are a heterogeneous group of inherited 71 
lysosomal storage disorders characterized by neurodegeneration and accumulation of 72 
autofluorescent lipopigments mainly in neurons. In human patients, they represent the 73 
most prevalent hereditary neurovisceral storage disorder with an incidence of 1.3 to 7 74 
for every 100,000 live births, depending on the country (Mole and Williams, 2001 75 
[Updated 2013]). Symptoms usually include blindness, motor and cognitive decline, 76 
seizures and premature death. The disease was originally classified on the basis of age 77 
of onset and clinical signs into congenital, infantile, late-infantile, juvenile and adult 78 
forms, with many possible variants (Mole and Williams, 2001 [Updated 2013]; 79 
Shacka, 2012). More than 400 different mutations in thirteen genes have been 80 
identified in human patients, and three genes have recently been suggested as – 81 
unproven – candidate genes (Di Fruscio et al., 2015). Despite coding for functionally 82 
distinct proteins   ̶  some soluble and some transmembrane proteins  ̶  mutations of 83 
these genes all induce accumulation of autofluorescence storage material (Shacka, 84 
2012). Mutations in different genes can result in similar phenotypes, whereas different 85 
mutations in the same gene can lead to a very different disease course. This rendered 86 
the original classification based on age of onset of limited value. The current 87 
characterization of NCL forms is now based on the causative mutation (Mole and 88 
Williams, 2001 [Updated 2013]).  89 
 90 
Numerous animal models of NCLs have been described and have been invaluable in 91 
contributing to the current understanding of this devastating condition. However, 92 
despite extensive research, the disease mechanisms are still not fully understood and 93 
animal models provide the opportunity to further understand the pathophysiology and 94 
assess new therapeutic strategies for each different form. In veterinary medicine, NCL 95 
has been described in various species including the sheep, cow, goat, horse, ferret, cat 96 
and dog (Jolly and Palmer, 1995; Anderson et al., 2013). In dogs, the causative 97 
mutation has been found in many breeds, including the American Bulldog (CLN10) 98 
(Awano et al., 2006), Border Collie (CLN5) (Melville et al., 2005), English Setter 99 
(CLN8) (Katz et al., 2005a), Dachshund (CLN1 and CLN2) (Awano et al., 2006; 100 
Sanders et al., 2010), Tibetan Terrier (ATP13A2 = CLN12) (Farias et al., 2011; 101 
Wohlke et al., 2011), Australian Shepherd (CLN6) (Katz et al., 2011), Golden 102 
Retriever (CLN5) (Gilliam et al., 2015), Australian Shepherd mix (CLN8) (Guo et al., 103 
2014) and more recently strongly suspected in a single Chinese Crested dog (MFSD8 104 
= CLN7) (Guo et al., 2015). Mutation in ARSG (Arylsulfatase G) has also been 105 
identified in the American Staffordshire Bull Terrier suffering from a lysosomal 106 
storage disorder initially classified as NCL (Abitbol et al., 2010); however, more 107 
recent reports suggest that ARSG-deficiency should be referred as a 108 
mucopolysaccharidosis (more precisely MPS IIIE) (Kowalewski et al., 2012; 109 
Kowalewski et al., 2015). Multiple sporadic reports of Chihuahua dogs affected by 110 
NCL exist (Rac and Giesecke, 1975; Kuwamura et al., 2003; Nakamoto et al., 2011), 111 
but, to date, the causative mutation has not been identified.  112 
We present here a family of Chihuahua dogs with a progressive neurological disease 113 
confirmed to be a form of NCL after histopathologic and ultrastructural examinations. 114 
After generating a whole genome sequence using DNA from one of the affected dogs, 115 
a mutation in MFSD8 (CLN7) gene was identified and this was confirmed by 116 
segregation analysis in the related dogs. The Chihuahua dog could represent a new 117 
animal model for CLN7 disease. 118 
 119 
MATERIAL AND METHODS 120 
1. Patient cohort – Clinical investigations 121 
Two littermate Chihuahua dogs (one male and one female) were presented to the 122 
Small Animal Hospital, University of Glasgow, for investigation of progressive 123 
neurological signs. Following clinical examination and routine complete blood count 124 
and biochemistry, they underwent magnetic resonance imaging (MRI) of the brain 125 
under general anesthesia. MR images were acquired using a 1.5 T (64 MHz) system 126 
(Magnetom Essenza, Siemens, Camberley, UK). T2-weighted, Fluid-attenuated 127 
inversion recovery, T2*-weighted, and T1-weighted images prior and after contrast 128 
were acquired in sagittal, transverse and dorsal planes. Routine cerebrospinal fluid 129 
analysis including total nucleated cell count, cytology and protein measurement was 130 
performed in the two affected cases and urinary organic acid screening by mass 131 
spectrometry was performed in the male dog.  132 
 133 
2. Histopathology and electron microscopy 134 
The male dog was euthanized at 1 year 11 months of age and underwent a full post-135 
mortem examination. Representative samples from the cerebrum and cerebellum were 136 
fixed in 2.5 % glutaraldehyde for electron microscopy (EM) analysis and other 137 
samples from the cerebrum and cerebellum were embedded in Tissue-Tek O.C.T 138 
(Sakura) and snapped frozen in isopentane chilled in liquid nitrogen before being 139 
stored at -80 °C for fluorescence microscopy. The rest of the brain, the eyes, and 140 
samples from skin, liver, kidney, adrenal, spleen, heart, duodenum and pancreas were 141 
fixed in 10 % buffered formalin. Slices of the formalin-fixed brain were then 142 
embedded in paraffin, before staining with hematoxilin and eosin (H&E), PAS, Sudan 143 
blue and Luxol fast blue. Samples for fluorescence microscopy were analysed as 144 
previously described (Katz et al., 2005b). Immunostaining was performed using 145 
antibodies directed against glial fibrillary acid protein (GFAP) and lysosomal-146 
associated membrane protein 1 (LAMP-1) (see Table I for details of antibodies used).  147 
 148 
3. Family analysis – Ethical statement 149 
The breeder of the affected dogs was contacted and agreed to provide DNA samples 150 
in the form of cheek swabs from the parents of the dogs and from related family 151 
members (Fig. 1). EDTA blood samples were available from the two affected dogs.  152 
Approval from the local ethical committee (University of Glasgow, School of 153 
Veterinary Medicine) was granted (Form Ref. 12a/14) for this study.  154 
 155 
4. Molecular analysis 156 
DNA was extracted from the blood of the two affected animals using a DNeasy Blood 157 
and Tissue kit (Qiagen, Crawley, UK) and from the cheek swabs using a Gentra 158 
Puregene Buccal Cell Kit (Qiagen, Crawley, UK).  159 
Whole-genome sequencing was performed on the affected female dog using 160 
Illumina’s TruSeq PCR free protocol according to the manufacturer’s instructions 161 
combined with Illumina’s Hiseq2000 on paired-end 100bp reads. Sequence alignment 162 
and variant calling were performed against the dog genome reference CanFam3.1 163 
using bwa (Li and Durbin, 2009) and the Genome Analysis Toolkit respectively 164 
(McKenna et al., 2010; DePristo et al., 2011), largely following the Best Practices v3, 165 
with hard filters for variant recalibration. In short, this consisted of duplicate read 166 
marking, realignment around indels, base quality score recalibration, variant 167 
identification using the HaplotypeCaller tool. High quality variants were annotated 168 
using snpEff (Cingolani et al., 2012) against the dog reference CanFam3.1.75. 169 
The data were initially analyzed for known NCL genes. Given the apparent autosomal 170 
recessive mode of transmission of the disease in the family, homozygous variants in 171 
the coding exons or splicing regions of previously described NCL genes were 172 
prioritized. Variants were identified in CLN6, ARSG, TPP1 and MFSD8 genes. 173 
Segregation analysis for these candidates was performed by Sanger sequencing. 174 
Following PCR amplification (see Table II for mutation location and primers used), 175 
the PCR products were purified using ExoSAP-IT (USB), before direct Sanger 176 
sequencing of both strands using BigDye Terminator v.3.1 chemistry v.3.1 (Applied 177 
Biosystems) and an ABI 3730XL Genetic Analyzer (Applied Biosystems). 178 
Sequencing traces were analyzed with Sequencher software v.4.2 (Gene Codes). 179 
 180 
RESULTS 181 
1. Clinical description of the patients 182 
The affected Chihuahua dogs were a 1-year 10 month old male neutered and a 2-year 183 
1 month old female at the time of presentation. The male started to demonstrate 184 
clinical signs at 1 year 4 months of age and the female at one year of age. They both 185 
demonstrated progressive vision deficits, pacing and behavioral changes. On 186 
examination, the dogs appeared disorientated, poorly responsive and were bumping 187 
into objects. They were ataxic on all limbs and had a wide-based stance. The female 188 
dog also demonstrated an intermittent right head tilt. Proprioceptive positioning was 189 
normal and there were mildly delayed hopping responses in all limbs. Segmental 190 
spinal reflexes were normal. Menace responses were absent bilaterally with intact 191 
dazzle reflexes and normal pupillary light reflexes. Remaining cranial nerves 192 
examination, segmental spinal reflexes and vertebral column palpation were within 193 
normal limits. No significant abnormalities were detected on physical examination, 194 
including eye fundus examination. A complete blood count and biochemistry were 195 
mainly unremarkable, with the exception of a moderate increase in liver enzymes and 196 
bile acid stimulation tests in the male dog (Alanine aminotransferase: 372 IU/L – 197 
reference interval (RI) <90; aspartate aminotransferase: 55 IU/L – RI<40; pre-198 
prandial bile acids: 5.3 µmol/L – RI<5 and post prandial bile acids: 50 µmol/L – 199 
RI<15). MRI in both cases demonstrated a severe dilatation of the entire ventricular 200 
system of the brain. The interthalamic adhesion appeared markedly decreased in size; 201 
the cerebellar sulci and the fissures between the cerebellar folia were noticeably 202 
widened. These changes suggested marked brain atrophy (Fig. 2A). Cerebrospinal 203 
fluid (CSF) analysis was unremarkable. Urine organic acids were measured by mass 204 
spectrometry in the male dog and were not suggestive of a disorder of organic acid 205 
metabolism.  206 
In light of the MRI changes, breed and in the absence of CSF abnormalities, a storage 207 
disease, and more specifically NCL, was highly suspected. The dogs were discharged 208 
with no treatment and the owners were warned of the very poor prognosis. Due to the 209 
deterioration of the clinical signs, both owners elected for euthanasia of their dogs 210 
within a month of discharge, but only the owners of the male dog agreed to post-211 
mortem examination. 212 
   213 
2. Histopathological features 214 
On gross examination of the brain, a moderate and symmetrical dilation of the lateral 215 
ventricles was noted, associated with a thin cortex. Histopathological examination 216 
demonstrated widespread amorphous to globular, eosinophilic to golden-brown, 217 
intracytoplasmic storage material within neurons and astrocytes within the cerebral 218 
cortex, basal ganglia, hippocampus, thalamus, brainstem and cerebellum (Fig. 2 and 219 
3). All storage material within astrocytes and neurons stained variably magenta with 220 
Periodic Acid-Schiff (PAS), variably positive with Sudan blue and intensively 221 
positive with Luxol fast blue (Fig. 2C and D). When viewed under a microscope 222 
equipped for epifluorescence illumination, as previously described (Katz et al., 223 
2005b), inclusion material fluoresced brightly (Fig. 2E). In the cortical grey matter 224 
neuronal necrosis was absent but neuronal density was reduced and remnant laminar 225 
neurons were disarrayed, and associated with an increased number of reactive 226 
astrocytes and activated microglia.  Within the cerebellum, Purkinje cells contained 227 
abundant intracytoplasmic storage material. There was some disorganization and a 228 
subjectively moderate decrease in the number of Purkinje cells, and several of the 229 
remaining Purkinje cells showed a mildly shrunken with hypereosinophilic cytoplasm 230 
and pyknotic nuclei (degeneration). Granular layer neurons were markedly reduced in 231 
density (Fig. 3). Neurons within the pyramidal layer of the hippocampus contained 232 
abundant intracytoplasmic storage but were present in normal numbers. 233 
Immunohistochemical staining confirmed the marked neuroinflammation with a high 234 
number of GFAP-positive astrocytes (Fig. 2G). Moreover, the tissue showed strong 235 
staining against LAMP-1 (lysosomal-associated membrane protein 1), indicative of 236 
alterations in this protein of the lysosome membrane (Fig. 2F).  Finally, ganglion cells 237 
within the retina were markedly reduced in number and when present contained 238 
abundant intracytoplasmic storage material (Fig. 2I). Storage material was also found 239 
in the duodenum, liver and heart using PAS staining and immunohistochemistry 240 
against LAMP-1. 241 
Based on these characteristics, NCL was diagnosed. NCL is a heterogeneous group of 242 
diseases, and further characterization involves ultrastructural analysis of the storage 243 
material. EM showed a complex multilamellar profile with presence of curvilinear 244 
and rectilinear profiles (Fig. 2H).  245 
 246 
3. Molecular analysis 247 
Non synonymous mutations in the following previously known NCL genes were 248 
identified: ARSG (p.Val262Asp, CLN6 (p.Lys29Arg), TPP1 (rs22973585) and 249 
MFSD8 (p.Phe282Leufs13*). ARSG, CLN6 and TPP1 variants did not segregate with 250 
the disease phenotype and were therefore excluded as the causative mutations. The 251 
MFSD8 single pair deletion segregated within the available members of the family, 252 
with affected dogs being homozygous for the mutation, both clinically unaffected 253 
parents heterozygous for the mutation and clinically unaffected relatives either 254 
heterozygous for the mutation or homozygous for the wild-type allele (Fig. 4). This 255 
mutation is predicted to result in a severely truncated protein, which further supports 256 
this to be the causal mutation.  257 
 258 
DISCUSSION 259 
In this study, we describe a family of dogs diagnosed with a mutation in MFSD8 260 
(CLN7) resulting in neuronal ceroid lipofuscinosis. The mutation is predicted to 261 
induce a frame shift leading to a premature stop codon.  262 
The two littermates were monitored for clinical signs of degenerative brain disease, 263 
mainly for the development of blindness, ataxia and cognitive impairment. These 264 
changes, secondary to marked brain atrophy, are very similar to those observed in 265 
patients affected with NCL or other animal forms of the disease. Presence of typical 266 
autofluorescent cytoplasmic inclusions associated with marked neuronal loss and 267 
astrocytosis confirmed the diagnosis of NCL. Numerous sporadic reports of 268 
Chihuahua dogs affected with NCL have been described in the literature with a total 269 
number of six previously described cases (Rac and Giesecke, 1975; Kuwamura et al., 270 
2003; Nakamoto et al., 2011). Similarities in age of onset, clinical signs and nature of 271 
the inclusion make it likely that these animals were affected by the same mutation as 272 
the dogs presented here. The previous descriptions concerned Chihuahua dogs from 273 
Japan and Australia, which suggests a world-wide distribution of the mutation. It may 274 
also be possible that the disease is not recognized by veterinarians, or that it is 275 
confused with other diseases such as hydrocephalus that is relatively common in the 276 
breed and can present with similar clinical signs. A commercial diagnostic test should 277 
be considered in order to determine the frequency of the mutations and to eradicate it 278 
from the breed.  279 
Interestingly, the same mutation has recently been strongly suspected as the cause of 280 
NCL in a single dog of another breed, the Chinese Crested, although lack of family 281 
ancestry did not allow further confirmation by segregation analysis (Guo et al., 2015). 282 
Our report is a further confirmation of this previously identified mutation. The clinical 283 
signs, age of onset, imaging and pathologic findings were very similar to that 284 
described here. The prevalence of the mutation in the Chinese crested population was 285 
extremely low (only one heterozygous animal out of 1478 tested Chinese crested), 286 
which makes it unlikely that a carrier animal could be found to start a colony to use as 287 
animal model. The presence of the identical mutation in the two breeds would suggest 288 
a common ancestor for the affected Chinese crested and Chihuahua dogs, possibly 289 
through another dog breed from Mexico, the Mexican hairless dog (Xoloitzcuintle). 290 
The Mexican hairless dogs and Chinese crested dogs are hairless dog breeds, which 291 
are very likely to be related as they carry an identical mutation at the origin of their 292 
alopecia (Drogemuller et al., 2008).   293 
 294 
To identify the mutation, we sequenced the whole genome of one of the affected dogs 295 
and compared it with the canine reference genome sequence. This allowed us to scan 296 
initially for sequence variants in the coding and splicing regions of the canine 297 
orthologs of the previously known genes to cause NCL in human patients. This 298 
approach has been previously reported by others and was successful at finding 299 
mutations causing NCL in dogs (Guo et al., 2014; Gilliam et al., 2015; Guo et al., 300 
2015). One of the genes (ARSG) considered as a candidate gene for NCL has now 301 
been re-classified as causative of a form of mucopolysaccharidosis (MPS IIIE) 302 
(Kowalewski et al., 2012; Kowalewski et al., 2015). However, the close proximity of 303 
these neurodegenerative disorders made exclusion of a mutation in this gene 304 
important.  305 
 306 
In human patients, mutations in the CLN7/MFSD8 gene generally result in a late-307 
infantile form, now called CLN7 disease. Symptoms are usually first noted between 308 
the age of 2 to 7 years with seizures and developmental regression. Progression of the 309 
disease results in motor and mental impairment, and blindness, leading to premature 310 
death occurring before adulthood in most patients (Kousi et al., 2012). Despite being a 311 
significant cause of late-infantile NCL in people (Aiello et al., 2009), very little is 312 
known about the pathophysiology of CLN7, which is in part due to (until recently) the 313 
lack of suitable animal models (Damme et al., 2014). MFSD8 is a lysosomal 314 
membrane protein belonging to the major facilitator superfamily (MFS). It is thought 315 
to act as a transporter but its substrate is still currently unknown (Damme et al., 2014). 316 
A mouse model of Mfsd8 disruption has been created and should contribute to a better 317 
understanding of this form of NCL, especially regarding the function of the protein 318 
and the disease mechanisms. Unfortunately, this model has limitations, as it does not 319 
accurately reproduce the clinical and histopathological findings seen in human 320 
patients (Damme et al., 2014). No obvious neuronal loss is observed in these mice, 321 
although marked accumulation of autofluorescent material in the nerve cells and 322 
retinal degeneration (photoreceptor layer) is evident. The failure to reproduce all key-323 
features of the human disease may be due to the presence of residual Cln7 protein 324 
function in these mice. In contrast, the Chihuahua dogs presented here could represent 325 
a better model as the histopathologic findings mimic the human pathology with 326 
marked neuronal loss and astrocytosis, resulting in progression of neurological signs 327 
incompatible with life (Table III). In the dog presented here, the Purkinje cells layer 328 
appears relatively spared - although signs of degeneration are visible – compared to 329 
what is observed in human patients. This difference could be due to the fact that the 330 
dog has been euthanized at a reasonably early stage of the disease. Indeed, this layer 331 
tends to be progressively lost in patients contrary to the granular cells layer, which is 332 
completely lost at very early age (Elleder et al., 2011). Overall, canine models are a 333 
good complement to murine models, especially for assessment of potential therapies 334 
due to a closer phenotype and longer lifespan (Faller et al., 2015). Additionally, the 335 
Chihuahua breed would be a particularly promising model due to its reasonably small 336 
size and ease of handling, which would make them particularly suitable as research 337 
individuals. However, further histological characterization of dogs of both sexes and 338 
of different ages would be needed for a better understanding of the progression of the 339 
disease.  340 
 341 
In conclusion, we have identified a mutation in MFSD8 causing Neuronal Ceroid 342 
Lipofuscinosis in Chihuahua dogs. This breed could represent a good animal model of 343 
CLN7 disease.  344 
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FIGURE LEGENDS  500 
 501 
Figure 1: Pedigree of the family of Chihuahua dogs. Solid figures represent affected 502 
dogs, whereas plain figures are clinically unaffected dogs. Squares represent males 503 
and circles females. Genotypes of the tested dogs are mentioned under each figure 504 
with WT = wild-type allele and Del = MFSD8:c.843delT:p.Phe282Leufs13* allele.  505 
 506 
Figure 2: Magnetic resonance imaging and histological findings of the male dog. A: 507 
Sagittal T2-weighted image of the brain. Note the marked generalised cerebral 508 
atrophy. B: H&E staining of the cerebellum at high magnification showing inclusions 509 
within the Purkinje cells (arrows). C & D: Periodic acid-Schiff (C) and Luxol Fast 510 
Blue (D) staining of brainstem neurons at high magnification. E:Fluorescence cryostat 511 
section of the cerebral cortex showing abundant autofluorescent inclusions. F & G: 512 
Lysosomal staining by use of anti-LAMP-1 antibody of the cerebellum of the affected 513 
dog (F) and of a control dog (G). H: Immunostaining against GFAP (brainstem). I: 514 
Electron microscopy of the storage bodies from the cerebral cortex. Note the mixed 515 
nature of the inclusions with curvilinear (*) and rectilinear (arrow) profiles. J. H&E 516 
staining of a retinal section. Note the marked depletion of the ganglion cells.  517 
NFL: nerve fiber layer. GCL: ganglion cell layer. IPL: inner plexiform layer. INL: 518 
inner nuclear layer. OPL: outer plexiform layer. ONL: outer nuclear layer. RL: 519 
receptor layer.   520 
 521 
Figure 3: H&E sections of the vermis of the cerebellum of the affected dog (A1 and 522 
A2) and of a control dog (B1 and B2) at low and high magnification. Note the marked 523 
depletion in granule cells in the affected dog (the blue line in each panel spans the 524 
granular layer). This results in an overall marked atrophy of the cerebellar cortex. In 525 
the affected dog, there is a moderate decrease in number of Purkinje cells (*), which 526 
show signs of degeneration. NB: in the control dog, at high magnification (B2), the 527 
white lamina is not seen due to the normal thickness of the granule cell layer, 528 
preventing visualisation of the white lamina in the same image as the three layers of 529 
cerebellar grey matter.  530 
 531 
Figure 4: Sequence traces showing a small portion of the genomic DNA of the 532 
Chihuahua dogs shown in the pedigree (Fig. 2), and centered around the mutation of 533 
interest (MFSD8:c.843delT:p.Phe282Leufs13*). All sequences are aligned against the 534 
canine reference genome (CanFam3.1).  535 
 536 
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Table I. Table of Primary Antibodies Used.  547  548 
Antigen Description of Immunogen 
Source, Host Species, 
Cat. #, Clone or Lot#, 
RRID 
Concentration Used 
LAMP-1 Lysosomal associated membrane protein 1 Abcam, mouse monoclonal, Cat# ab25630 RRID : AB_470708 1:200   Glial fibrillary acidic protein (GFAP) GFAP isolated from bovine spinal cord Dako, Rabbit monoclonal, Cat# Z0334, RRID:AB_2314535 1:1000  549 550 
Table II: Homozygous variants in the coding region or splicing areas of previously 551 
known NCL genes used for Sanger sequencing confirmation and segregation 552 
analyses.  553 
Gene 
(transcript) 
Variant 
location Primers 
ARSG 
(XM_005624176.1) 
p.Val262Asp 
 
F: 5’-ACCTCTTGGCTTTCCCATTG-3’ 
R: 5’-CAGGGAGCTAGCTGGGTTTT-3’ 
CLN6 
(NM_001011888.1) 
p.Lys29Arg F: 5’-CACAGTGCTTCCCGCAAC-3’ 
R: 5’-CACCAAAACCGCATCCTACT-3’ 
TPP1 
(NM_001013847.1) 
Splice site 
(rs22973585) 
F: 5’-GCTCACAGTGTGCACATGTG-3’ 
R: 5’-GAGTACCTGATGAGTGCCGG-3’ 
CLN7/ MFSD8 
(XM_533294.4) 
c.843delT; 
p.F282Lfs13* 
F: 5’-ATCTCCTGGGAAGAAAATTCAC-3’ 
R: 5’-TTAAATCATGGCACTGAAGTTTT-3’ 
 554 
Only the mutation identified in MFSD8:c.843delT:p.Phe282Leufs13* segregated with 555 
the disease in the studied family. 556  557  558 559 
Table III: Comparison of the phenotypes of human CLN7 disease, the Mfsd8(tm1a/tm1a) 560 
mouse model (Damme et al., 2014) and the canine model described here and in the 561 
literature.  562 
Neuropathological 
features 
CLN7 disease 
(humans) 
Mfsd8(tm1a/tm1a) (mice)  
(Damme et al 2014) 
CLN7 disease 
(canine) 
Retinal degeneration Yes Yes Yes (this report, 
Kuwamura et al., 
2003) 
Accumulation of 
SCMAS (Sub-unit C 
of mitochondrial ATP 
synthase) 
Yes Yes Not performed 
Accumulation of 
autofluorescent ceroid 
lipopigments 
Yes Yes Yes (this report; 
Kuwamura et al., 
2003; Guo et al., 
2015) 
Astrogliosis Yes Only mildly Yes (this report, Guo 
et al., 2015; 
Kuwamura et al., 
2003; Nakamoto et al., 
2011) 
Generalised seizures Yes No No (this report; Guo et 
al., 2015; Kuwamura 
et al., 2003) 
Suspected partial 
seizure (jaw 
chomping) (Rac et al., 
1975) 
Terminal stage 
(Nakamoto et al., 
2011) 
Myoclonus/ataxia Yes Yes Yes (ataxia) (this 
report; Guo et al., 
2015; Rac et al., 1975; 
Nakamoto et al., 
2011) 
Neuronal loss / brain 
atrophy 
Yes No Yes (this report, Guo 
et al., 2015; Rac et al., 
1975; Nakamoto et al., 
2011; Kuwamura et 
al., 2003) 
Premature death Yes (mean age 11.5 
years) (Kousi et al 
No Yes (euthanasia as not 
compatible with life) – 
2009) ~ 1.5 - 2 years (lifespan 
of a Chihuahua or a 
Chinese Crested dog > 
12 years) (this report; 
Kuwamura et al., 2003; 
Rac et al., 1975; 
Nakamoto et al., 2011; 
Guo et al., 2015). 
Table adapted from Damme et al. (2014) 563 
